Mineralys Therapeutics Announces First Subject Dosed in Launch-HTN, the Second Pivotal Trial of Lorundrostat for the Treatment of Hypertension

December 21, 2023

https://www.globenewswire.com/news-release/2023/12/21/2800342/0/en/Mineralys-Therapeutics-Announces-First-Subject-Dosed-in-Launch-HTN-the-Second-Pivotal-Trial-of-Lorundrostat-for-the-Treatment-of-Hypertension.html

– Topline data from confirmatory Launch-HTN trial expected in 2H 2025 –

– Topline data from ongoing Advance-HTN pivotal trial expected in 2H 2024 –

Read more at globenewswire.com

Related news for (MLYS)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.